InflaRx (NASDAQ:IFRX) Stock Price Down 0.8% - Should You Sell?

Key Points

• InflaRx's stock price decreased by 0.8% to $1.24, with trading volume dropping 5% compared to the average.
• Analysts have mixed ratings on InflaRx, with a total of five analysts giving it a "Buy" rating and one "Sell," and a consensus price target of $6.20.
• Institutional investors own 42.39% of InflaRx's stock, with significant increases in holdings from firms like Cubist Systematic Strategies and OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT.

InflaRx N.V. (NASDAQ:IFRX - Get Free Report) fell 0.8% during trading on Thursday . The company traded as low as $1.18 and last traded at $1.24. 452,416 shares changed hands during mid-day trading, a decline of 5% from the average session volume of 474,873 shares. The stock had previously closed at $1.25.

Analyst Upgrades and Downgrades

A number of research firms recently commented on IFRX. HC Wainwright began coverage on InflaRx in a research report on Tuesday, September 2nd. They issued a "buy" rating and a $6.00 price target for the company. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of InflaRx in a research report on Tuesday. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, InflaRx currently has an average rating of "Moderate Buy" and a consensus price target of $6.20.

InflaRx Trading Down 0.8%

The stock has a market capitalization of $83.24 million, a PE ratio of -1.55 and a beta of 1.40. The firm has a 50-day moving average price of $1.26 and a 200-day moving average price of $1.14.

InflaRx (NASDAQ:IFRX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.24) earnings per share for the quarter, hitting the consensus estimate of ($0.24). The firm had revenue of $0.05 million during the quarter, compared to analysts' expectations of $0.02 million. Sell-side analysts expect that InflaRx N.V. will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InflaRx

Large investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC increased its holdings in InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock worth $31,000 after acquiring an additional 7,616 shares during the last quarter. XTX Topco Ltd purchased a new stake in InflaRx in the 1st quarter worth about $38,000. Concurrent Investment Advisors LLC purchased a new stake in InflaRx in the 2nd quarter worth about $65,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in InflaRx by 158.3% in the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company's stock worth $118,000 after acquiring an additional 91,927 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in InflaRx in the 2nd quarter worth about $262,000. Hedge funds and other institutional investors own 42.39% of the company's stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.